UL acquires Safeware Quasar to expand regulatory compliance and supply chain solutions

UL, a global safety science leader, today announced the acquisition of Safeware Quasar, a market leader in chemical regulatory compliance software and consultancy solutions, to expand UL’s supply chain data management and global regulatory compliance expertise.

Safeware Quasar, a privately-held company based in Nottingham, U.K., is a recognized leader in developing and providing chemical compliance solutions to assist customers in meeting regulatory demands.

UL acquired Safeware to strengthen its ability to serve customers in Europe with leading compliance software and advisory services, extend supplier qualification offerings and enhance its safety data sheet distribution capabilities.

Chemical regulatory compliance is a growing concern as consumers and regulators alike demand transparency and regulation of toxic chemicals,”

Carlos Correia, SVP and General Manager of Supply Chain and Sustainability for UL.

“The combination of UL’s existing supply chain data management and global regulatory compliance services with Safeware will provide assurance to all stakeholders of the chemical value chain, and help clients keep up with an increasingly complex regulatory environment.”

UL and Safeware Quasar’s combined portfolio will help strengthen global relationships with key customers. In addition, Safeware will leverage UL’s global scale and resources to expand into new markets.

“Our clients will benefit from UL’s global enhanced range of compliance products and services,” said Hazi Mistry, Managing Director of Safeware Quasar. “We look forward to continuing to work with our existing customers and are very excited by the acquisition.”

Safeware Quasar’s employees will join UL and remain with the company. Safeware Quasar will be led by Hazi Mistry, Managing Director of Safeware, reporting up to Lou DeSorbo, UL Vice President and General Manager of Information and Insights. The transaction closed on August 31, 2016.

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Through the eyes of a cat – biomimicry of feline eyes may revolutionize robotic vision